Cardiac effects of cholinesterase inhibitors: A reason for restraint?;Cardiale neveneffecten van cholinesteraseremmers: Een reden tot terughoudendheid in voorschrijven?

Tijdschrift voor Gerontologie en Geriatrie

Volumn 40, Issue 2, 2009, Pages 79-84

  Salarbaks, A M ^a   Boomkamp Snoeren, C M ^a   Van Puijenbroek, E ^b   Jansen, P A F ^a   Van Marum, R J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Nederlands Bijwerkingencentrurn Lareb ^*

Author keywords

Cardiac safety; Cholinesterase inhibitors; Dementia; Side effects

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CISAPRIDE; CLARITHROMYCIN; DICLOFENAC; DIGOXIN; DILTIAZEM; DOMPERIDONE; ERYTHROMYCIN; FLUCONAZOLE; GALANTAMINE; HYDROCHLOROTHIAZIDE; ITRACONAZOLE; KETOCONAZOLE; LACTULOSE; LOSARTAN; METOPROLOL; PANTOPRAZOLE; PAPAVERINE; PARACETAMOL; PHENTOLAMINE; RIVASTIGMINE; ROSUVASTATIN; SPIRONOLACTONE; TEMAZEPAM; TERBINAFINE; UNINDEXED DRUG; VERAPAMIL;

ACUTE HEART INFARCTION; AGED; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAM; FOOD DRUG INTERACTION; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; PATHOPHYSIOLOGY; PATIENT MONITORING; SYNCOPE;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FATAL OUTCOME; FEMALE; HEART FAILURE; HUMANS; MALE; NOOTROPIC AGENTS;

EID: 65449139105     PISSN: 01679228     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137-47.
2. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Then 20o8;117(2):232-43. Epub 2007 Dec 20.
3. Wilkinson DG, Francis PT, Schwam E, Payne- Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21(7):453-78.
4. Tavassoli N, Sommet A, Lapeyre-Mestre M, Bag- heri H, Montrastruc JL.Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies(Vidal, British National Formulary). Drug Saf. 2007;3o11):1o63-71.
5. Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with
6. cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17(13):947-63.
7. Masuda Y. Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease-from basic research to bedside. Curr Alzheimer Res. 2004 Nov;1(4):315-21.
8. Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42(5):558-568
9. Ballard C, Lane R, Barone P, Ferrara R, Tekin S. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 20o6;6o(6):639-645.
10. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321(7274):1445-1449
11. McLaren AT, Allen J, Murray A, Ballard CG, Kenny RA. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15(4):183-188
12. Bordier P, Garrigue S, Lanusse S et al. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.CNS Drugs 2006; 2o(5):411-417.
13. Leentjes AFG, Kragten JA. Totaal atrioventriculair blok tijdens behandeling met galantamine. Nederlands Tijdschrift voor Genees- kunde.2006; 150:563-566.
14. Kayrak M, Yazici M,Ayhan SS, Koc F, Ulgen MS. Complete atrioventricular block associated with rivastigmine therapy. Am J Health Syst Pharm. 20o8;65(11):1o51-3.
15. Walsh E, Dourish J. Prolonged QT interval with rivastigmine. Br J Psychiatry 2002; 180:466.
16. Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother. 2oo8;42(2):278-83.
17. Suleyman T, Tevfik P, Abdulkadir G, Ozlem S. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J. 20o6;23(8):641-2.
18. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ,Wang D, Brashear HR, Nye JS; The GAL-INT-11/18 Study Group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 20o8;70(22):2024-2035.
19. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR,Berlin JA, Battisti WP, Kavanagh S. Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurol Scand. 2008 Jun 1. [Epub ahead of print]
20. Lopez-Pousa S, Olmo JG, Franch JV, Estrada AT, Cors OS, Nierga IP, Gelada-Batlle E. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age Ageing. 2oo6;35(4):365-71.
21. Roisin T., van Ermen A., Rogiers A. Cardiac Adverse Effects with Cholinesterase Inhibitors, (abstract no 34). Drug Safety 20o6;29(1o):911- 1011
22. Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;3o(2):239-45.